CÂNCER DE OVÁRIO: UMA REVISÃO INTEGRATIVA DE LITERATURA

Autores

  • Cristina Alessandra Zachow Bühring Universidade de Cruz Alta - UNICRUZ, Cruz Alta, RS, Brasil
  • Luana Schayene Wagner Universidade de Cruz Alta - UNICRUZ, Cruz Alta, RS, Brasil
  • Isadora Kottwitz da Silva Universidade de Cruz Alta - UNICRUZ, Cruz Alta, RS, Brasil
  • Graziella Alebrant Mendes Universidade de Cruz Alta - UNICRUZ, Cruz Alta, RS, Brasil

DOI:

https://doi.org/10.33053/revint.v9i1.641

Palavras-chave:

Carcinoma epitelial ovariano, Suscetibilidade genética, Terapia., Diagnóstico, Saúde da mulher

Resumo

O Câncer de Ovário desenvolve-se nos ovários, sendo que, 70% das pacientes são diagnosticadas em estágios avançados e 90% das mortes são devidas aos subtipos de alto grau. O objetivo do estudo foi identificar as abordagens das produções científicas relacionadas ao câncer de ovário, considerando os fatores de risco e desenvolvimento tumoral, diagnóstico e tratamento. Foi realizada uma revisão integrativa de literatura através do PUBMED, SciELO e EBSCO, o critério de inclusão foram artigos científicos internacionais e nacionais disponíveis na íntegra gratuitamente, publicados de 2010 a 2020 e que consentissem a temática do estudo. Foram incluídos 18 artigos científicos no estudo. Cerca 90% dos carcinomas ovarianos são de origem epitelial. A patogênese é influenciada por fatores extrínsecos e intrínsecos, tais como histórico familiar de câncer de mama ou ovário, mutações em BRCA1 e BRCA2 e lesão precursora causada pela endometriose. Os sintomas inicias são inespecíficos e testes de triagem incluem exames de imagem, como ultrassonografia transvaginal e dosagem sérica de marcadores tumorais, principalmente CA-125. A distribuição dos glóbulos vermelhos, o volume médio plaquetário e osteoponina, podem ser utilizadas no diagnóstico diferencial de lesões malignas e benignas. O tratamento geralmente consiste de terapia local, com cirurgia citorredutora e radioterapia, seguida de quimioterapia a base de platina. Estudos constantes são necessários para aprimorar os métodos de diagnóstico e tratamentos.

Referências

ALSOP, Kathryn; et al. BRCA mutation frequency and patterns of treatment response in BRCA mutation–positive women with ovarian cancer: a report from the Australian Ovarian Cancer Study Group. Journal of Clinical Oncology, v. 30, n. 21, p. 2654, 2012.

BRASIL. Câncer de ovário, Ministério da saúde. Instituto Nacional do Câncer. 2021.

BRASILEIRO FILHO, Geraldo. Bogliolo patologia geral. In: Bogliolo patologia geral. 6. ed. 2019.

BOLTON, Kelly L.; et al. Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer. Jama, v. 307, n. 4, p. 382-389, 2012.

CONSOLARO, M. E. L.; MARIA-ENGLER, S. S. Citologia Clínica Cérvico-Vaginal. São Paulo, 2014.

CORTÉS MORERA, Alejandro; et al. Cáncer de Ovario: Tamizaje y diagnóstico imagenológico. Medicina Legal de Costa Rica, v. 37, n. 1, p. 54-61, 2020.

COSTANZO, Linda S. Fisiologia. Elsevier, 2018.

DE OLIVEIRA, Katiele Marques; DE OLIVEIRA, Murielly Marques; ARAUJO, Raquel Soares. Câncer de ovário e detecção precoce: revisão bibliográfica da literatura. Revista Científica FacMais, v. 7, n. 3, 2016.

FORTNER, Renée T.; et al. Reproductive and hormone related risk factors for epithelial ovarian cancer by histologic pathways, invasiveness and histologic subtypes: results from the EPIC cohort. International Journal of Cancer, v. 137, n. 5, p. 1196-1208, 2015.

DOUBENI, Chyke A.; DOUBENI, Anna R.; MYERS, Allison E. Diagnosis and management of ovarian cancer. American Family Physician, v. 93, n. 11, p. 937-944, 2016.

GAONA ESTUDILLO, Rubí. El cáncer de ovario, el asalto del homicida invisible. Revista de la Facultad de Medicina (México), v. 57, n. 1, p. 24-30, 2014.

GILKS, C. Blake. Molecular abnormalities in ovarian cancer subtypes other than high grade serous carcinoma. Journal of Oncology, v. 2010, 2010.

GRAAFF, Van De; KENT M. Anatomia Humana. Ed. Manole Ltda. 6. ed. 2013.

HARDING, Barbara N.; et al. Use of statin medications following diagnosis in relation to survival among women with ovarian cancer. Cancer Epidemiology and Prevention Biomarkers, v. 28, n. 7, p. 1127-1133, 2019.

HARRIS, Holly R.; et al. Polycystic ovary syndrome, oligomenorrhea, and risk of ovarian cancer histotypes: evidence from the Ovarian Cancer Association Consortium. Cancer Epidemiology and Prevention Biomarkers, v. 27, n. 2, p. 174-182, 2018.

HELPMAN, L.; et al. Young women with epithelial ovarian cancer: Prevalence of BRCA mutations and clinical correlates. Gynecologic Oncology, v. 141, p. 90, 2016.

HORALA, Agnieszka; et al. Diagnostic value of serum angiogenesis markers in ovarian cancer using multiplex immunoassay. International Journal of Molecular Sciences, v. 18, n. 1, p. 123, 2017.

JAMMAL, Millena Prata; et al. Is ovarian cancer prevention currently still a recommendation of our grandparents?. Revista Brasileira de Ginecologia e Obstetrícia, v. 39, n. 12, p. 676-685, 2017.

JIA, Dongyu; et al. Inflammation is a key contributor to ovarian cancer cell seeding. Scientific Reports, v. 8, n. 1, p. 1-7, 2018.

KIM, Hee Seung; et al. Risk and prognosis of ovarian cancer in women with endometriosis: a meta-analysis. British Journal of Cancer, v. 110, n. 7, p. 1878-1890, 2014.

KLYMENKO, Yuliya; NEPHEW, Kenneth P. Epigenetic crosstalk between the tumor microenvironment and ovarian cancer cells: a therapeutic road less traveled. Cancers, v. 10, n. 9, p. 295, 2018.

KRÁLÍCKOVÁ, Milena et al. Endometriosis and risk of ovarian cancer: what do we know? Archives of Gynecology and Obstetrics, v. 301, n. 1, p. 1-10, 2020.

KUBECEK, Ondrej; et al. The pathogenesis, diagnosis, and management of metastatic tumors to the ovary: a comprehensive review. Clinical & Experimental Metastasis, v. 34, n. 5, p. 295-307, 2017.

KURMAN, Robert J.; SHIH, Ie Ming. The Origin and pathogenesis of epithelial ovarian cancer-a proposed unifying theory. The American Journal of Surgical Pathology, v. 34, n. 3, p. 433, 2010.

KURMAN, Robert J.; SHIH, Ie Ming. The dualistic model of ovarian carcinogenesis: revisited, revised, and expanded. The American Journal of Pathology, v. 186, n. 4, p. 733-747, 2016.

KURMAN, Robert J.; SHIH, Ie Ming. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer shifting the paradigm. Human Pathology, v. 42, p. 918-931, 2011.

LOVEDAY, Chey; et al. Germline mutations in RAD51D confer susceptibility to ovarian cancer. Nature Genetics, v. 43, n. 9, p. 879-882, 2011.

MAVADDAT, Nasim; et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiology and Prevention Biomarkers, v. 21, n. 1, p. 134-147, 2012.

MERRITT, Melissa A.; CRAMER, Daniel W. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomarkers, v. 9, n. 1-6, p. 287-305, 2011.

PAES, Marcela F.; et al. A retrospective analysis of clinicopathological and prognostic characteristics of ovarian tumors in the State of Espírito Santo, Brazil. Journal of Ovarian Research, v. 4, n. 1, p. 14, 2011.

PERES, Lauren C.; et al. Invasive epithelial ovarian cancer survival by histotype and disease stage. JNCI: Journal of the National Cancer Institute, v. 111, n. 1, p. 60-68, 2019.

POOLE, Elizabeth M.; et al. Endometriosis and risk of ovarian and endometrial cancers in a large prospective cohort of US nurses. Cancer Causes & Control, v. 28, p. 437-445, 2017.

QIN, Yuan-yuan; et al. Single and combined use of red cell distribution width, mean platelet volume, and cancer antigen 125 for differential diagnosis of ovarian cancer and benign ovarian tumors. Journal of Ovarian Research, v. 11, n. 1, p. 10, 2018.

RAMOS, Marcelo Cristiano de Azevedo; et al. Cost effectiveness of the cancer prevention program for carriers of the BRCA1/2 mutation. Revista de Saúde Pública, v. 52, p. 94, 2018.

RICHARDS, JoAnne S.; et al. The ovary: basic biology and clinical implications. The Journal of Clinical Investigation, v. 120, n. 4, p. 963-972, 2010.

ROJAS, Veronica; et al. Molecular characterization of epithelial ovarian cancer: implications for diagnosis and treatment. International Journal of Molecular Sciences, v. 17, n. 12, p. 2113, 2016.

ROY, Rohini; CHUN, Jarin; POWELL, Simon N. BRCA1 and BRCA2: different roles in a common pathway of genome protection. Nature Reviews Cancer, v. 12, n. 1, p. 68-78, 2012.

SHINMURA, Hiroki et al. Use of tumor markers to distinguish endometriosis related ovarian neoplasms from ovarian endometrioma. International Journal of Gynecologic Cancer, v. 30, n. 6, 2020.

SUNG, Ho Kyung; et al. The effect of breastfeeding duration and parity on the risk of epithelial ovarian cancer: a systematic review and meta-analysis. Journal of Preventive Medicine and Public Health, v. 49, n. 6, p. 349, 2016.

TAYLOR, Jolyn S.; et al. Disparities in treatment and survival among elderly ovarian cancer patients. Gynecologic Oncology, v. 151, n. 2, p. 269-274, 2018.

TEMKIN, Sarah M.; et al. Ovarian cancer prevention in high risk women. Clinical Obstetrics and Gynecology, v. 60, n. 4, p. 738, 2017.

WANG, Yuxuan; et al. Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers. Science Translational Medicine, v. 10, n. 433, 2018.

WARREN, Laura A.; et al. Analysis of menstrual effluent: diagnostic potential for endometriosis. Molecular Medicine, v. 24, n. 1, p. 1-12, 2018.

WENTZENSEN, Nicolas; et al. Ovarian cancer risk factors by histologic subtype: an analysis from the ovarian cancer cohort consortium. Journal of Clinical Oncology, v. 34, n. 24, p. 2888, 2016.

Downloads

Publicado

2021-12-16

Como Citar

Zachow Bühring, C. A., Schayene Wagner, L., Kottwitz da Silva, I., & Alebrant Mendes, G. (2021). CÂNCER DE OVÁRIO: UMA REVISÃO INTEGRATIVA DE LITERATURA. REVISTA INTERDISCIPLINAR DE ENSINO, PESQUISA E EXTENSÃO, 9(1), 199-211. https://doi.org/10.33053/revint.v9i1.641

Edição

Seção

Mostra de Iniciação Científica - Ciências Biológicas e da Saúde